Skopos Labs, Inc. Rhythm Pharmaceuticals, Inc. Transaction History
Skopos Labs, Inc.
- $497 Million
- Q2 2025
A detailed history of Skopos Labs, Inc. transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Skopos Labs, Inc. holds 5 shares of RYTM stock, worth $568. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5
Previous 5
-0.0%
Holding current value
$568
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding RYTM
# of Institutions
255Shares Held
64.4MCall Options Held
210KPut Options Held
575K-
Black Rock Inc. New York, NY6.74MShares$767 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY5.6MShares$638 Million3.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.56MShares$633 Million7.68% of portfolio
-
Primecap Management CO Pasadena, CA4.88MShares$555 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.59MShares$408 Million0.0% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $6.34B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...